2019年冠状病毒病(COVID-19)在儿童年龄组中的患病率

Saber A. M. El-Sayed, Mostafa M. Ahmady, Bashir Abdalla Hassan
{"title":"2019年冠状病毒病(COVID-19)在儿童年龄组中的患病率","authors":"Saber A. M. El-Sayed, Mostafa M. Ahmady, Bashir Abdalla Hassan","doi":"10.47752//SJMH.41.40.45","DOIUrl":null,"url":null,"abstract":"In our study prevalence of coronavirus Disease 2019 (COVID-19) among Children age groups, by diagnosis, symptoms, and treatment of COVID-19 in children. The incidence of COVID-19 among children under 18 years was 1.8 % based on the reported studies, where the mortality rate in the same age group was 0.3 %. No death has been reported in children under 10-years old. It has also been reported that the case fatality rates for the age groups of 0-9 years and 10-19 years are zero and 0.2%, respectively. Cai, et al. [1] There are some studies that report children with COVID-19 having rashes, symptoms and signs similar to Kawasaki’s disease. Heart complications were observed in these cases of Kawasaki’s disease. the levels of bilirubin and hepatic enzymes are the best markers for diagnosing the severity of the disease in the affected children. Large number of angiotensin converting enzyme 2 (ACE2) receptors on cell surfaces, effective innate immune system, and high level of blood lymphocyte have been reported to be the potent reasons for lower incidence of severe symptoms of COVID-19 among children. Children with severe COVID-19 clinical symptoms, especially those suffering from upper respiratory tract symptoms and signs and pneumonia, also children with gastrointestinal tract symptoms and signs as vomiting and diarrhea must be hospitalized similar to adults, while quarantine and home isolations are required for those having mild symptoms. Antiviral medication (Remdesivir, darunavir, ribavirin, oseltamivir, tocilizumab, umifenovir and favipiravir,) ACE inhibitors, interferon-α 2b, co-therapy with azithromycin, inhaling iNO, inhaled bronchodilators and oxygen therapy can be used for treatment. The best treatment for affected children without any clinical and infection symptoms, home isolation protocol has been recommended.","PeriodicalId":93143,"journal":{"name":"Sumerianz journal of medical and healthcare","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevalence of Coronavirus Disease 2019 (COVID-19) Among Children Age Groups\",\"authors\":\"Saber A. M. El-Sayed, Mostafa M. Ahmady, Bashir Abdalla Hassan\",\"doi\":\"10.47752//SJMH.41.40.45\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In our study prevalence of coronavirus Disease 2019 (COVID-19) among Children age groups, by diagnosis, symptoms, and treatment of COVID-19 in children. The incidence of COVID-19 among children under 18 years was 1.8 % based on the reported studies, where the mortality rate in the same age group was 0.3 %. No death has been reported in children under 10-years old. It has also been reported that the case fatality rates for the age groups of 0-9 years and 10-19 years are zero and 0.2%, respectively. Cai, et al. [1] There are some studies that report children with COVID-19 having rashes, symptoms and signs similar to Kawasaki’s disease. Heart complications were observed in these cases of Kawasaki’s disease. the levels of bilirubin and hepatic enzymes are the best markers for diagnosing the severity of the disease in the affected children. Large number of angiotensin converting enzyme 2 (ACE2) receptors on cell surfaces, effective innate immune system, and high level of blood lymphocyte have been reported to be the potent reasons for lower incidence of severe symptoms of COVID-19 among children. Children with severe COVID-19 clinical symptoms, especially those suffering from upper respiratory tract symptoms and signs and pneumonia, also children with gastrointestinal tract symptoms and signs as vomiting and diarrhea must be hospitalized similar to adults, while quarantine and home isolations are required for those having mild symptoms. Antiviral medication (Remdesivir, darunavir, ribavirin, oseltamivir, tocilizumab, umifenovir and favipiravir,) ACE inhibitors, interferon-α 2b, co-therapy with azithromycin, inhaling iNO, inhaled bronchodilators and oxygen therapy can be used for treatment. The best treatment for affected children without any clinical and infection symptoms, home isolation protocol has been recommended.\",\"PeriodicalId\":93143,\"journal\":{\"name\":\"Sumerianz journal of medical and healthcare\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sumerianz journal of medical and healthcare\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47752//SJMH.41.40.45\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sumerianz journal of medical and healthcare","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47752//SJMH.41.40.45","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在我们的研究中,通过儿童新冠肺炎的诊断、症状和治疗,儿童年龄组中2019冠状病毒病(新冠肺炎)的患病率。根据报告的研究,18岁以下儿童中新冠肺炎的发病率为1.8%,同一年龄组的死亡率为0.3%。目前尚无10岁以下儿童死亡的报告。据报告,0-9岁和10-19岁年龄组的病死率分别为零和0.2%。蔡等人[1]有一些研究报告称,患有新冠肺炎的儿童出现与川崎病相似的皮疹、症状和体征。在这些川崎病病例中观察到了心脏并发症。胆红素和肝酶水平是诊断患病儿童疾病严重程度的最佳标志物。据报道,细胞表面大量的血管紧张素转换酶2(ACE2)受体、有效的先天免疫系统和高水平的血淋巴细胞是儿童新冠肺炎严重症状发生率较低的有力原因。患有严重新冠肺炎临床症状的儿童,特别是患有上呼吸道症状和体征以及肺炎的儿童,以及患有呕吐和腹泻等胃肠道症状和体征的儿童,必须像成年人一样住院治疗,而症状轻微的儿童则需要隔离和居家隔离。抗病毒药物(Remdesivir、达芦那韦、利巴韦林、奥司他韦、托西珠单抗、乌米芬诺韦和法匹拉韦)ACE抑制剂、干扰素-α2b、阿奇霉素联合治疗、吸入iNO、吸入支气管扩张剂和氧气治疗可用于治疗。对于没有任何临床和感染症状的受影响儿童,建议采用家庭隔离方案进行最佳治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prevalence of Coronavirus Disease 2019 (COVID-19) Among Children Age Groups
In our study prevalence of coronavirus Disease 2019 (COVID-19) among Children age groups, by diagnosis, symptoms, and treatment of COVID-19 in children. The incidence of COVID-19 among children under 18 years was 1.8 % based on the reported studies, where the mortality rate in the same age group was 0.3 %. No death has been reported in children under 10-years old. It has also been reported that the case fatality rates for the age groups of 0-9 years and 10-19 years are zero and 0.2%, respectively. Cai, et al. [1] There are some studies that report children with COVID-19 having rashes, symptoms and signs similar to Kawasaki’s disease. Heart complications were observed in these cases of Kawasaki’s disease. the levels of bilirubin and hepatic enzymes are the best markers for diagnosing the severity of the disease in the affected children. Large number of angiotensin converting enzyme 2 (ACE2) receptors on cell surfaces, effective innate immune system, and high level of blood lymphocyte have been reported to be the potent reasons for lower incidence of severe symptoms of COVID-19 among children. Children with severe COVID-19 clinical symptoms, especially those suffering from upper respiratory tract symptoms and signs and pneumonia, also children with gastrointestinal tract symptoms and signs as vomiting and diarrhea must be hospitalized similar to adults, while quarantine and home isolations are required for those having mild symptoms. Antiviral medication (Remdesivir, darunavir, ribavirin, oseltamivir, tocilizumab, umifenovir and favipiravir,) ACE inhibitors, interferon-α 2b, co-therapy with azithromycin, inhaling iNO, inhaled bronchodilators and oxygen therapy can be used for treatment. The best treatment for affected children without any clinical and infection symptoms, home isolation protocol has been recommended.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信